1312946-11-4

Upstream product

• 1312949-15-7 1-methyl-3-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-6(7H)-one 
• 10199-50-5 1-methyl-3-phenyl-1H-pyrazol-5-amine 
• 614-16-4 Benzoylacetonitrile 
• 93-58-3 benzoic acid methyl ester 
• 936939-96-7 rac-1-(3,5-dimethyl-1H-pyrazol-4-yl)ethanamine 
• 1335220-04-6 (1-Methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yloxy)-acetic acid 

Downstream Products

• 1312946-36-3 (R)-N-(1-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl)-2-(1-methyl-3-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-6-yloxy)acetamide 
• 1312945-84-8 (S)-N-(1-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl)-2-(1-methyl-3-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-6-yloxy)acetamide 

Relevant academic research and scientific papers

Discovery of 1H-pyrazolo[3,4-b]pyridines as potent dual orexin receptor antagonists (DORAs)

Compound rac-1 was identified by high throughput screening. Here we report SAR studies and MedChem optimization towards the highly potent dual orexin receptor antagonists (S)-2 and (S)-3. Furthermore, strategies to overcome the suboptimal physicochemical properties are highlighted and the pharmacokinetic profiles of representative compounds is presented.

DISUBSTITUTED HETEROARYL-FUSED PYRIDINES

The invention relates to compound of the formula (I') in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.